These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 16291873

  • 1. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs.
    Perry M, Stansfeld PJ, Leaney J, Wood C, de Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS.
    Mol Pharmacol; 2006 Feb; 69(2):509-19. PubMed ID: 16291873
    [Abstract] [Full Text] [Related]

  • 2. Structural determinants of HERG channel block by clofilium and ibutilide.
    Perry M, de Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J.
    Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
    [Abstract] [Full Text] [Related]

  • 3. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241.
    Suessbrich H, Schönherr R, Heinemann SH, Lang F, Busch AE.
    FEBS Lett; 1997 Sep 08; 414(2):435-8. PubMed ID: 9315735
    [Abstract] [Full Text] [Related]

  • 4. Molecular determinants of hERG channel block by terfenadine and cisapride.
    Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC.
    J Pharmacol Sci; 2008 Nov 08; 108(3):301-7. PubMed ID: 18987434
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue.
    Varkevisser R, Houtman MJ, Linder T, de Git KC, Beekman HD, Tidwell RR, Ijzerman AP, Stary-Weinzinger A, Vos MA, van der Heyden MA.
    Br J Pharmacol; 2013 Jul 08; 169(6):1322-34. PubMed ID: 23586323
    [Abstract] [Full Text] [Related]

  • 7. Molecular determinants of HERG channel block.
    Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC.
    Mol Pharmacol; 2006 May 08; 69(5):1709-16. PubMed ID: 16474003
    [Abstract] [Full Text] [Related]

  • 8. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
    Ficker E, Obejero-Paz CA, Zhao S, Brown AM.
    J Biol Chem; 2002 Feb 15; 277(7):4989-98. PubMed ID: 11741928
    [Abstract] [Full Text] [Related]

  • 9. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant.
    Hosaka Y, Iwata M, Kamiya N, Yamada M, Kinoshita K, Fukunishi Y, Tsujimae K, Hibino H, Aizawa Y, Inanobe A, Nakamura H, Kurachi Y.
    Channels (Austin); 2007 Feb 15; 1(3):198-208. PubMed ID: 18690032
    [Abstract] [Full Text] [Related]

  • 10. The low-potency, voltage-dependent HERG blocker propafenone--molecular determinants and drug trapping.
    Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC, Mitcheson JS.
    Mol Pharmacol; 2004 Nov 15; 66(5):1201-12. PubMed ID: 15308760
    [Abstract] [Full Text] [Related]

  • 11. Open channel block of HERG K(+) channels by vesnarinone.
    Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC.
    Mol Pharmacol; 2001 Aug 15; 60(2):244-53. PubMed ID: 11455010
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine.
    Sánchez-Chapula JA, Navarro-Polanco RA, Sanguinetti MC.
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Dec 15; 370(6):484-91. PubMed ID: 15558243
    [Abstract] [Full Text] [Related]

  • 14. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications.
    Thomas D, Karle CA, Kiehn J.
    Curr Pharm Des; 2006 Dec 15; 12(18):2271-83. PubMed ID: 16787254
    [Abstract] [Full Text] [Related]

  • 15. A structural basis for drug-induced long QT syndrome.
    Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC.
    Proc Natl Acad Sci U S A; 2000 Oct 24; 97(22):12329-33. PubMed ID: 11005845
    [Abstract] [Full Text] [Related]

  • 16. Physicochemical features of the HERG channel drug binding site.
    Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC.
    J Biol Chem; 2004 Mar 12; 279(11):10120-7. PubMed ID: 14699101
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.
    Sánchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC.
    J Biol Chem; 2002 Jun 28; 277(26):23587-95. PubMed ID: 11960982
    [Abstract] [Full Text] [Related]

  • 19. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
    Ficker E, Jarolimek W, Brown AM.
    Mol Pharmacol; 2001 Dec 28; 60(6):1343-8. PubMed ID: 11723241
    [Abstract] [Full Text] [Related]

  • 20. Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues.
    Louvel J, Carvalho JF, Yu Z, Soethoudt M, Lenselink EB, Klaasse E, Brussee J, Ijzerman AP.
    J Med Chem; 2013 Dec 12; 56(23):9427-40. PubMed ID: 24224763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.